Arcturus Therapeutics warns of severe risks from OTC deficiency

Arcturus Therapeutics warns of severe risks from OTC deficiency
OTC deficiency risks

Ornithine transcarbamylase (OTC) deficiency presents significant health risks when ammonia builds up in the body. Arcturus Therapeutics highlights the critical role OTC plays in the urea cycle and warns of the life-threatening symptoms that can arise if the enzyme's function is impaired.

The biotechnology firm emphasizes the urgency of addressing these deficiencies, which, if unrecognized, can lead to serious illnesses. With their expertise, Arcturus Therapeutics is voicing concerns to enhance awareness and urge further research into potential treatments and solutions.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.